Bronchogen vs LL-37

Bronchogen wins for targeted recovery of airway epithelium, normalization of post-insult mucus and cilia, and long-term support in high-risk pulmonary protocols. Its track record for restoring bronchial structure (including ciliated-cell balance and secretory IgA) sets it apart for lung or airway rejuvenation without the flare risk.

LL-37 wins for rapid, broad-spectrum antimicrobial effects, biofilm disruption, and wound healing—especially in cases where persistent infection, chronic inflammation, or slow tissue remodeling dominate. Its direct antibacterial, antifungal, and antiviral coverage is superior for infectious or post-surgical scenarios, but comes with a higher risk profile for users prone to autoimmunity or inflammatory dermatoses.

Pick Bronchogen if:

• The research protocol targets post-viral or post-irritant airway repair (ex-smoker, ex-vaper, endurance athlete in polluted air).
• The goal is to counteract mucus accumulation and restore epithelial cilia (especially after high-GH/cardiac output cycles).
• The literature aims for geroprotective effects and long-term normalization of lung tissue gene expression.
• Airway remodeling or repair is needed without aggressively stimulating innate immunity.
• Pulmonary support is being stacked with other Khavinson bioregulators (e.g. Epitalon, Cardiogen).

Pick LL-37 if:

• Disruption of difficult or chronic infections (resistant bacteria, biofilms, viral/fungal coinfection) is the primary endpoint.
• Wound healing acceleration is a focus—non-healing ulcers, surgical recovery, or post-Hair transplant use-cases.
• The protocol involves clearing persistent sinus, skin, or mucosal issues where antibiotics have stalled out.
• Local administration to target-site inflammation is possible and no history of autoimmune or inflammatory skin conditions is present.
• Stacking with immune- or repair-peptides (BPC-157, GHK-Cu, thymosin alpha-1) for synergistic tissue and immune support is desired.